IL173862A0 - Therapeutic beta aminoacids - Google Patents
Therapeutic beta aminoacidsInfo
- Publication number
- IL173862A0 IL173862A0 IL173862A IL17386206A IL173862A0 IL 173862 A0 IL173862 A0 IL 173862A0 IL 173862 A IL173862 A IL 173862A IL 17386206 A IL17386206 A IL 17386206A IL 173862 A0 IL173862 A0 IL 173862A0
- Authority
- IL
- Israel
- Prior art keywords
- aminoacids
- therapeutic beta
- therapeutic
- beta aminoacids
- beta
- Prior art date
Links
- 150000001576 beta-amino acids Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50600303P | 2003-09-25 | 2003-09-25 | |
| PCT/IB2004/002978 WO2005030184A2 (en) | 2003-09-25 | 2004-09-13 | Therapeutic beta aminoacids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL173862A0 true IL173862A0 (en) | 2006-07-05 |
Family
ID=34393101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL173862A IL173862A0 (en) | 2003-09-25 | 2006-02-21 | Therapeutic beta aminoacids |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7112610B2 (OSRAM) |
| EP (1) | EP1670452A2 (OSRAM) |
| JP (1) | JP2007506726A (OSRAM) |
| KR (1) | KR100774625B1 (OSRAM) |
| CN (1) | CN1856301A (OSRAM) |
| AU (1) | AU2004275572A1 (OSRAM) |
| BR (1) | BRPI0414798A (OSRAM) |
| CA (1) | CA2539976A1 (OSRAM) |
| IL (1) | IL173862A0 (OSRAM) |
| MX (1) | MXPA06003381A (OSRAM) |
| NO (1) | NO20061801L (OSRAM) |
| RU (2) | RU2344121C2 (OSRAM) |
| TW (1) | TW200511989A (OSRAM) |
| WO (1) | WO2005030184A2 (OSRAM) |
| ZA (1) | ZA200602450B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012158795A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| EA025496B1 (ru) | 2011-05-17 | 2016-12-30 | Принсипиа Биофарма Инк. | Ингибиторы тирозинкиназы |
| HUE048834T2 (hu) | 2011-05-17 | 2020-08-28 | Univ California | Kináz inhibitorok |
| US9266895B2 (en) | 2012-09-10 | 2016-02-23 | Principia Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| EP4681737A3 (en) | 2014-02-21 | 2026-03-11 | Principia Biopharma Inc. | Salts and solid form of a btk inhibitor |
| US10485797B2 (en) | 2014-12-18 | 2019-11-26 | Principia Biopharma Inc. | Treatment of pemphigus |
| TW201718572A (zh) | 2015-06-24 | 2017-06-01 | 普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
| IL293621B2 (en) | 2016-06-29 | 2023-09-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile |
| JP7795454B2 (ja) | 2019-10-14 | 2026-01-07 | プリンシピア バイオファーマ インコーポレイテッド | （ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することにより免疫性血小板減少症を治療する方法 |
| AU2021209884A1 (en) | 2020-01-22 | 2022-09-15 | Principia Biopharma Inc. | Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2256370T3 (es) * | 1991-08-23 | 2006-07-16 | Nps Pharmaceuticals, Inc. | Moleculas activas para el receptor de calcio. |
| US6306909B1 (en) * | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
| FR2791982B1 (fr) * | 1999-04-06 | 2002-12-27 | Inst Nat Sante Rech Med | Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques. |
| WO2002073208A2 (en) * | 2001-03-13 | 2002-09-19 | Queen's University At Kingston | Anti-epileptogenic agents |
| NI200300043A (es) * | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
| GB0219024D0 (en) * | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| US20050043345A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| US20050043406A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
-
2004
- 2004-09-13 RU RU2006107650/04A patent/RU2344121C2/ru not_active IP Right Cessation
- 2004-09-13 CN CNA2004800277659A patent/CN1856301A/zh active Pending
- 2004-09-13 AU AU2004275572A patent/AU2004275572A1/en not_active Abandoned
- 2004-09-13 EP EP04769367A patent/EP1670452A2/en not_active Withdrawn
- 2004-09-13 JP JP2006527499A patent/JP2007506726A/ja not_active Withdrawn
- 2004-09-13 WO PCT/IB2004/002978 patent/WO2005030184A2/en not_active Ceased
- 2004-09-13 KR KR1020067005783A patent/KR100774625B1/ko not_active Expired - Fee Related
- 2004-09-13 CA CA002539976A patent/CA2539976A1/en not_active Abandoned
- 2004-09-13 BR BRPI0414798-7A patent/BRPI0414798A/pt not_active IP Right Cessation
- 2004-09-13 MX MXPA06003381A patent/MXPA06003381A/es unknown
- 2004-09-24 TW TW093129003A patent/TW200511989A/zh unknown
- 2004-09-24 US US10/950,094 patent/US7112610B2/en not_active Expired - Fee Related
-
2006
- 2006-02-21 IL IL173862A patent/IL173862A0/en unknown
- 2006-03-24 ZA ZA200602450A patent/ZA200602450B/en unknown
- 2006-04-24 NO NO20061801A patent/NO20061801L/no not_active Application Discontinuation
- 2006-06-30 US US11/480,010 patent/US20060247282A1/en not_active Abandoned
-
2008
- 2008-09-19 RU RU2008137379/04A patent/RU2008137379A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004275572A1 (en) | 2005-04-07 |
| NO20061801L (no) | 2006-06-02 |
| WO2005030184A3 (en) | 2005-06-02 |
| US20050124669A1 (en) | 2005-06-09 |
| JP2007506726A (ja) | 2007-03-22 |
| CA2539976A1 (en) | 2005-04-07 |
| BRPI0414798A (pt) | 2006-11-21 |
| US20060247282A1 (en) | 2006-11-02 |
| TW200511989A (en) | 2005-04-01 |
| US7112610B2 (en) | 2006-09-26 |
| WO2005030184A2 (en) | 2005-04-07 |
| RU2006107650A (ru) | 2007-10-27 |
| RU2344121C2 (ru) | 2009-01-20 |
| CN1856301A (zh) | 2006-11-01 |
| KR20060056391A (ko) | 2006-05-24 |
| MXPA06003381A (es) | 2006-06-08 |
| ZA200602450B (en) | 2007-09-26 |
| RU2008137379A (ru) | 2010-03-27 |
| EP1670452A2 (en) | 2006-06-21 |
| KR100774625B1 (ko) | 2007-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0307918D0 (en) | Therapeutic use | |
| EP1603543A4 (en) | THERAPEUTIC COMPOSITIONS | |
| AU2003279911A8 (en) | Therapeutic formulations | |
| EP1556023A4 (en) | NUTRITIONAL OR THERAPEUTIC COMPOSITIONS | |
| GB0222945D0 (en) | Therapeutic compositions | |
| AU2003282722A8 (en) | Therapeutic compositions | |
| EP1607316A4 (en) | COMBINED | |
| GB0219660D0 (en) | Therapeutic use | |
| IL174308A0 (en) | Therapeutic formulations | |
| GB0310123D0 (en) | Airfreshener combined luminair | |
| GB0212821D0 (en) | Eyewash | |
| GB0314406D0 (en) | Padded structure | |
| AU2003231937A8 (en) | Therapeutic methods | |
| GB0303289D0 (en) | Combination therapy | |
| GB0213383D0 (en) | Therapeutic conditions | |
| GB0325021D0 (en) | Therapeutic combinations | |
| GB0215011D0 (en) | Easy squeezy | |
| GB0313363D0 (en) | Therapeutic combinations | |
| AU3172P (en) | Just Blush Ozothamnus diosmifolius | |
| GB0228652D0 (en) | Therapeutic compositions | |
| GB0228227D0 (en) | Therapeutic compositions | |
| GB0311733D0 (en) | Couch | |
| AU151008S (en) | Stanchion | |
| TW522879U (en) | Improvement for SPA sprinkle-nozzle | |
| GB0322990D0 (en) | Therapeutic use |